No abstract

No abstract

No abstract

S105system (FAERS) database. A retrospective descriptive analysis was conducted to explore the frequency of VOD in all patients who had taken GO and Inotuzumab Ozogamicin and reported adverse event to FDA from 2000 to 2016. Our study focused mainly on reports of VOD associated with the use of either "Gemtuzuamb ozogamicin" or "Inotuzmab ozogamicin". ReSultS: A total of 200 adverse reports of VOD were retrieved from FAERS database.

newly diagnosed FLT3-mutated AML patient Ͻ60 years was estimated at $114,193 compared to $105,819 for patients with non-FLT3-mutated AML. As early mortality and early retirement were not included in indirect costs, these may be underestimated. CONCLUSIONS: FLT3-mutated AML potentially represents a greater per-patient burden than non-FLT3-mutated AML due to shorter survival and greater use of stem cell transplants. Investigational treatments targeting the FLT3 mutation may provide an additional therapeutic option and have the potential to improve clinical outcomes.